We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Cara
Flynn
+44 (0)116 258 3692
caf26@leicester.ac.uk
Prof
Chris
Brightling
+44 (0)116 250 2704
ceb17@leicester.ac.uk
Chronic obstructive pulmonary disease
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Chronic obstructive pulmonary disease (COPD) is a highly common chronic lung disease which carries a significant burden for both patients and healthcare systems. Treatment has been limited for several years. Recent studies have shown a promising new target in treating asthma – thymic stromal lymphopoietin (TSLP) is a protein released when the airways are irritated. This causes an increase in airway inflammation and therefore the symptoms of COPD. Blocking or reducing this with a medication called tezepelumab has been shown to reduce airway inflammation in asthma. Other studies have also shown reduced symptoms and exacerbations in a diverse group of asthma patients, including those who do not demonstrate a high level of allergic-type inflammation. This study will investigate the effect of this medication on the airways of people who suffer from COPD.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
You can take part if:
You may not be able to take part if:
1. History of unstable or severe cardiac, hepatic, thyrotoxicosis, concomitant respiratory or renal disease, or other medically significant illness, which the investigator believes, would be a contraindication to study participation. 2. Significant concomitant respiratory disease such as cystic fibrosis, pulmonary fibrosis, aspergillosis, active or untreated primary tuberculosis. 3. Any significant abnormal laboratory results at screening, which in the opinion of the investigator, may put the subject at risk to take part in the study, 4. Current diagnosis of Asthma 5. Previous Lung volume reduction surgery for the indication of COPD 6. Any use of home oxygen therapy 7. Patients with clinically significant laboratory abnormalities (not associated with the study indication) at screening 8. Recent acute exacerbation event requiring oral corticosteroids or antibiotics (any dose for more than 3 days) or respiratory tract infection 4 weeks prior to screening 9. History of active Malignancy in any organ system (diagnosis within last 12 months or ongoing active cancer treatment such as chemotherapy, radiotherapy, or immunotherapy. 10. History of treatment with biologics within four months or five half-lives (whichever is longer) prior to screening. 11. History of anaphylaxis to any biologic therapy or sensitivity of any component of IMP formulation 12. Have been involved in another medicinal trial (CTIMP) within the past 28 days 13. Women who are pregnant, lactating or intend to become pregnant during the study period 14. Planned surgical procedures requiring general anaesthesia or in-patient status for > 1 day during the conduct of the study. 15. Receipt of any live or attenuated vaccines within 15 days prior to screening 16. Patients whose treatment is considered palliative (life expectancy < 6 months). 17. History of chronic alcohol or drug abuse within 12 months prior to screening 18. Receipt of immunoglobulin or blood products within 30 days prior to screening 19. Use of immunosuppressive medication (e.g., methotrexate, troleandomycin, oral gold, cyclosporine, azathioprine, intramuscular long-acting depot corticosteroid) within 3 months prior to screening. 20. History of any known primary immunodeficiency disorder excluding asymptomatic selective immunoglobulin A or IgG subclass deficiency. 21. Subject taking antiretroviral medications, as determined by medical history 22. History of human immunodeficiency virus (HIV) or hepatitis B or C.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Prof
Chris
Brightling
+44 (0)116 250 2704
ceb17@leicester.ac.uk
Dr
Cara
Flynn
+44 (0)116 258 3692
caf26@leicester.ac.uk
The study is sponsored by University of Leicester and funded by AstraZeneca.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Or CPMS 60939
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
